Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 10/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | GUSB | P08236 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4479905 | 0.96 | GLA (0.59) | GLAALDH1A1MAPTEGFRERBB2 | |
| SCHEMBL13672248 | 0.95 | GLA (0.58) | GLAALDH1A1MAPTEGFRERBB2 | |
| SCHEMBL4974615 | 0.94 | GLA (0.59) | GLAALDH1A1MAPTEGFRERBB2 | |
| SCHEMBL13672243 | 0.93 | GLA (0.60) | GLAALDH1A1MAPTEGFRERBB2 | |
| SCHEMBL4470314 | 0.92 | GLA (0.65) | GLAALDH1A1MAPTEGFRERBB2 | |
| SCHEMBL4977557 | 0.91 | GLA (0.64) | GLAALDH1A1MAPTEGFRERBB2 | |
| SCHEMBL13672245 | 0.90 | GLA (0.63) | GLAALDH1A1MAPTEGFRERBB2 | |
| SCHEMBL4488576 | 0.90 | GLA (0.57) | GLAALDH1A1MAPTEGFRERBB2 | |
| SCHEMBL4475274 | 0.89 | GLA (0.68) | GLAALDH1A1MAPTEGFRERBB2 | |
| SCHEMBL13672244 | 0.89 | GLA (0.61) | GLAALDH1A1MAPTEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685114-B1 | ANTIBACTERIAL AND/OR ANTIPROTOZOAL NITROIMIDAZOLE DERIVATIVE COMPOUNDS WITH UREASE INHIBITOR ACTIVITY, PROCESS FOR PREPARING THESE COMPOUNDS AND USE IN PHARMACEUTICAL COMPOSITIONS AND MEDICINES. | EMS SA (BR) | 2008-10-15 | — | — | EP | claimed |
| US-7608724-B2 | 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-[(aminocarbonothioyl)amino]-4-oxobutanoate;potententiation; anaerobic/ aerobic microoraganisms; grampositive,gramnegative bacteria; Campylobacter; respiratory system disorders; paraciticides; nontoxic; enzymers/hydrolases/;enzyme inhibitors | EMS S.A. (BR) | 2009-10-27 | — | — | US | disclosed |
| US-7608724-B2 | 2-(2-Methyl-5-nitro-1H-imidazol-1-yl)ethyl 4-[(aminocarbonothioyl)amino]-4-oxobutanoate;potententiation; anaerobic/ aerobic microoraganisms; grampositive,gramnegative bacteria; Campylobacter; respiratory system disorders; paraciticides; nontoxic; enzymers/hydrolases/;enzyme inhibitors | EMS S.A. (BR) | 2009-10-27 | — | — | US | disclosed |
| US-20070072929-A1 | Antibacterial and/or antiprotozoal nitromidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines | EMS S.A. (BR) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072929-A1 | Antibacterial and/or antiprotozoal nitromidazole derivative compounds with urease inhibitor activity, process for preparing these compounds and use in pharmaceutical compositions and medicines | UMPS, PNP, UROD | GLA 1180/4885ALDH1A1 2614/4885MAPT 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.